Upadacitinib Is a Better Choice than Abrocitinib for Patients with Moderate-to-Severe Atopic Dermatitis: An Updated Meta-Analysis
Table 3
Result of adverse events.
Synthesis outcome (EOT)
RCTs
No. of groups
Patients#
Evidence synthesis
I2(%)
value
Egger’s test
Grade
Any treatment-emergent adverse events
JAK1 inhibitors
8
19
4389
OR 1.41 [1.26, 1.57]
0
0.0004
0.2613
High
Abrocitinib
4
10
1640
OR 1.40 [1.16, 1.68]
0
<0.00001
0.0292
Moderate
Upadacitinib
4
9
2749
OR 1.41 [1.23, 1.61]
0
<0.00001
0.7974
High
Subgroup differencea
0
0.94
Abrocitinib (100 mg vs. 200 mg)
4
4
1198
OR 0.83 [0.66, 1.05]
21
0.12
0.5968
Moderate
Upadacitinib (15 mg vs. 30 mg)b
4
4
1805
OR 0.76 [0.63, 0.93]
6
0.007
0.7923
High
Serious adverse events
JAK1 inhibitors
8
19
4389
OR 0.76 [0.55, 1.05]
0
0.09
0.7783
Moderate
Abrocitinib
4
10
1640
OR 0.77 [0.46, 1.31]
0
0.34
0.7475
Moderate
Upadacitinib
4
9
2749
OR 0.75 [0.50, 1.13]
0
0.17
0.9884
Moderate
Subgroup differencea
0
0.93
Acne
JAK1 inhibitors
7
15
4122
OR 6.59 [4.72, 9.18]
0
<0.00001
0.3581
High
Abrocitinib
3
6
1373
OR 7.54 [2.34, 24.26]
0
0.0007
0.0037
High
Upadacitinib
4
9
2749
OR 6.48 [4.59, 9.16]
0
<0.00001
0.2444
High
Subgroup differencea
0
0.81
Upper respiratory tract infection
JAK1 inhibitors
8
19
4389
OR 1.26 [1.03, 1.55]
0
0.03
0.1640
High
Abrocitinib
4
10
1640
OR 1.05 [0.72, 1.54]
0
0.79
0.4009
Moderate
Upadacitinib
4
9
2749
OR 1.36 [1.06, 1.74]
0
0.01
0.9410
High
Subgroup differencea
20.1
0.26
Nasopharyngitis
JAK1 inhibitors
7
15
4122
OR 1.38 [1.13, 1.69]
0
0.002
0.0899
High
Abrocitinib
3
6
1373
OR 1.34 [0.93, 1.93]
0
0.12
0.5263
Moderate
Upadacitinib
4
9
2749
OR 1.40 [1.10, 1.78]
0
0.005
0.0924
High
Subgroup differencea
0
0.83
Headache
JAK1 inhibitors
8
19
4389
OR 1.59 [1.24, 2.03]
0
0.0002
0.0028
Low
Abrocitinib
4
10
1640
OR 2.04 [1.31, 3.16]
0
0.001
0.0706
High
Upadacitinib
4
9
2749
OR 1.40 [1.04, 1.89]
0
0.03
0.1006
High
Subgroup differencea
47.7
0.17
Nausea
JAK1 inhibitors
5
13
1806
OR 4.77 [2.92, 7.81]
0
<0.00001
0.0309
High
Abrocitinib
4
10
1640
OR 5.18 [3.05, 8.81]
0
<0.00001
0.2046
High
Upadacitinib
1
3
166
OR 2.29 [0.58, 9.08]
0
0.24
<0.0001
Low
Subgroup differencea
14.7
0.28
Coloring mark means extremely magnitude of effect (OR ≤ 0.2 or OR ≥ 5). EOT = End of treatment. #Duplicate number of patients in the control group had been removed. value ≤0.05. aWe compare the risk between abrocitinib and upadacitinib, value >0.05 means there is an insignificant difference between abrocitinib and upadacitinib. bWe compare the risk between different doses of upadacitinib, value <0.05 means 15 mg upadacitinib has lower risk of any treatment-emergent adverse events.
